{
  "id": 10939787,
  "title": "Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis",
  "url": "https://urgent.news/2026/09/30/eupraxia-pharmaceuticals-reports-52-week-data-from-the-highest-dose",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-30T12:13:08.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/eupraxia-pharmaceuticals-reports-52-week-data-from-the-highest-dose-cohort-of-ep-104gi-in-its-ongoing-phase-1b-2a-resolve-trial-for-the-treatment-of-eosinophilic-esophagitis"
  },
  "original_language": "en",
  "account": null,
  "summary": "The highest dose group of EP-104GI (Cohort 9) demonstrated durability of symptom responses out to 52 weeks, with 66% of patients (2 of 3) maintaining clinical remission1 The second highest dose group of EP-104GI (Cohort 8b) continued to show meaningful histologic reduction in inflammation and fibrosis with Stage –0.26 and Grade –0.27 in EoEHSS at […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Vietnam Investment Review",
        "title": "Innovent Biologics expands Phase 3 lung cancer trial globally",
        "url": "https://urgent.news/2026/09/28/innovent-biologics-expands-phase-3-lung-cancer-trial-globally",
        "published": "2026-09-28T07:12:04.000Z"
      },
      {
        "outlet": "Investing.com",
        "title": "Phathom Pharmaceuticals begins Phase 3 trial for VOQUEZNA in non-erosive GERD",
        "url": "https://urgent.news/2026/09/29/phathom-pharmaceuticals-begins-phase-3-trial-for-voquezna-in-non",
        "published": "2026-09-29T20:56:43.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}